| -0.08 / -0.22%|
The 9 analysts offering 12-month price forecasts for Haemonetics Corp have a median target of 46.00, with a high estimate of 51.00 and a low estimate of 33.00. The median estimate represents a +24.26% increase from the last price of 37.02.
The current consensus among 12 polled investment analysts is to Buy stock in Haemonetics Corp. This rating has held steady since March, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.